Ken Griffin Ac Immune Sa Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	SELL	$2.66 - $4.87 $10,374 - $18,993	-3,900 Reduced 33.62%	7,700 $22,000
Q4 2023 Feb 14, 2024	SELL	$2.46 - $5.0 $27,060 - $55,000	-11,000 Reduced 48.67%	11,600 $58,000
Q3 2023 Nov 14, 2023	SELL	$2.77 - $3.38 $14,681 - $17,914	-5,300 Reduced 19.0%	22,600 $64,000
Q2 2023 Aug 14, 2023	BUY	$1.85 - $3.4 $34,595 - $63,580	18,700 Added 203.26%	27,900 $82,000
Q1 2023 May 15, 2023	BUY	$2.13 - $2.49 $12,141 - $14,193	5,700 Added 162.86%	9,200 $21,000

Q4 2022 Feb 14, 2023	SELL	$1.72 - $3.12 $13,072 - $23,712	-7,600 Reduced 68.47%	3,500 $7,000
Q3 2022 Nov 14, 2022	BUY	$2.4 - $3.64 $26,640 - $40,404	11,100 New	11,100 $35,000

29M

92.9K

46.3K

Ticker ACIU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,413,504
Market Cap $333M
Description
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectiv...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.